Common Blood Pressure Medication Telmisartan Found to Significantly Enhance Performance of Targeted Cancer Therapies

Dartmouth researchers find that the hypertension drug telmisartan makes tumors more vulnerable to targeted therapies and triggers a stronger immune response.

By: AXL Media

Published: Mar 26, 2026, 10:17 AM EDT

Source: Information for this report was sourced from Dartmouth Health

Repurposing Hypertension Medication for Oncology

A new study led by the Dartmouth Cancer Center has identified a significant clinical synergy between the FDA-approved blood pressure medication telmisartan and the targeted cancer therapy olaparib. According to the research published in The Journal for ImmunoTherapy of Cancer, this common and affordable drug could substantially improve the efficacy of a critical class of oncology treatments. Lead author Tyler J. Curiel noted that the findings suggest a safe, well-tolerated, and convenient medication may hold the key to expanding the reach of advanced therapies to a much broader patient population than previously possible.

Expanding the Utility of PARP Inhibitors

PARP inhibitors like olaparib are traditionally effective only in tumors with specific DNA repair defects, such as those carrying BRCA mutations. However, many cancers lack these vulnerabilities or eventually develop a resistance to the treatment, which has historically limited the number of eligible patients. According to the Dartmouth team, telmisartan effectively induces a state of vulnerability in tumors even when they lack those specific genetic defects. This discovery implies that the drug can artificially create the conditions necessary for PARP inhibitors to successfully attack and destroy malignant cells.

A Dual Mechanism of Action

In preclinical evaluations, the combination of telmisartan and olaparib was found to increase direct DNA damage within tumor cells while simultaneously triggering powerful immune-stimulating signals. The researchers observed a significant boost in the production of type I interferons, which are molecules that assist the immune system in identifying and targeting cancerous growths. According to Curiel, this specific immune activation is a primary driver behind the treatment's success, as it essentially strips away the biological camouflage that many tumors use to hide from the body's natural defenses.